# Alexander Hardy

> Alexander Hardy is President and Chief Executive Officer of BioMarin and a member of its board. He joined in December 2023 after leading Genentech and holding regional and global roles at Roche. His earlier career included GSK, PathoGenesis and Novartis; he studied at Cambridge and earned a Michigan Ross MBA in 1992.

- **Role:** President and Chief Executive Officer at BioMarin Pharmaceutical Inc.
- **Organizations:** BioMarin Pharmaceutical Inc., Genentech, Roche, Novartis, PathoGenesis, GSK, Pharmaceutical Research and Manufacturers of America (PhRMA)
- **Education:** B.A. in Land Economy, University of Cambridge, M.B.A., University of Michigan, Ross School of Business
- **Known for:** Led Roche’s Asia Pacific organization across 19 countries., Led Roche’s Global Product Strategy organization and co-chaired its late-stage portfolio committee., Selected to succeed BioMarin’s CEO after a multi-year board succession process.

## Career timeline

- **Early career** — Interned at Eli Lilly; subsequently worked at SmithKline Beecham (now GSK), PathoGenesis and Novartis.
- **Before 2005** — Held Novartis roles including country head for Denmark and head of market access for Europe.
- **2005** — Joined Genentech.
- **2014-2016** — Head of Asia Pacific for Roche Pharmaceuticals, responsible for 19 countries and more than 6,000 employees.
- **2016-2019** — Head of Global Product Strategy at Roche Pharmaceuticals.
- **2019-03** — Became Genentech CEO, effective March 1.
- **2023-12** — Became President, CEO and a board member of BioMarin, effective December 1.
- **2024-09** — Presented BioMarin’s new corporate strategy; participated in its Nasdaq listing anniversary celebration.
- **2026-04** — BioMarin completed its acquisition of Amicus Therapeutics during his tenure.

## Achievements

- Led Roche’s Asia Pacific organization across 19 countries.
- Led Roche’s Global Product Strategy organization and co-chaired its late-stage portfolio committee.
- Selected to succeed BioMarin’s CEO after a multi-year board succession process.
- Serves on the PhRMA board.

## Latest updates

- **2026-10** — BioMarin appointed Cara Bauer Chief People Officer, succeeding Amy Wireman; Hardy publicly recognized Wireman’s contributions.
- **2026-04** — BioMarin completed its approximately $4.8 billion equity-value acquisition of Amicus Therapeutics on April 27.
- **2025-07** — BioMarin acquired Inozyme Pharma.

## Links

- Website: https://www.biomarin.com/company/leadership/alexander-hardy/
- LinkedIn: https://www.linkedin.com/in/alexanderhardybiomarin

---

Profile page: https://yespress.io/alexander-hardy
Published by YesPress — https://yespress.io
Last updated: 2026-10-24